Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eltoprazine for levodopa-induced dyskinesia in Parkinson's disease
2015-000373-13Phase 2Suspended
- Sponsor
- Amarantus BioScience
- Start
- May 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of eltoprazine in Parkinson's disease (PD) and levodopa-induced dyskinesia (LID) (4 arms), sponsored by Amarantus BioScience. Primary endpoint: Safety and tolerability. Started May 2015; status: suspended.
02
Drugs
eltoprazine
03
Conditions
Parkinson's disease (PD)levodopa-induced dyskinesia (LID)
Beyond the preview
Go deeper on 2015-000373-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-000373-13.